Patients
13.1 % of adults
Diabetes (adults), Singapore, 2022 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Vidhi Upadhyay
Singapore Smart Insulin Pens Market Industry Trends and Forecast to 2034: Segmented by (Type, Connectivity, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $0.2 Mn | — | — |
| 2025 (base) | $0.3 Mn | +$0.0 Mn | — |
| 2026 (forecast) | $0.3 Mn | +$0.1 Mn | +18.9% |
| 2027 (forecast) | $0.4 Mn | +$0.1 Mn | +41.4% |
| 2028 (forecast) | $0.5 Mn | +$0.1 Mn | +68.1% |
| 2029 (forecast) | $0.6 Mn | +$0.1 Mn | +99.9% |
| 2030 (forecast) | $0.7 Mn | +$0.1 Mn | +137.6% |
| 2031 (forecast) | $0.8 Mn | +$0.1 Mn | +182.5% |
| 2032 (forecast) | $0.9 Mn | +$0.2 Mn | +235.9% |
| 2033 (forecast) | $1.1 Mn | +$0.2 Mn | +299.4% |
| 2034 (forecast) | $1.3 Mn | +$0.2 Mn | +374.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $0.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, connectivity and end user (see all) |
| Key players | Novo Nordisk A/S, Medtronic, Bigfoot Biomedical, Sanofi, Biocorp (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Smart insulin pens record each dose and send it to an app, helping people with diabetes track insulin and avoid missed or double doses.
Key segments of the smart Insulin Pens market include type (Reusable Smart Pens and Smart Pen Caps and Attachments) and connectivity (Bluetooth and NFC).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the smart Insulin Pens market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the smart Insulin Pens market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the smart Insulin Pens market. Long-term safety data and lifestyle support are still needed for many patients.
The smart Insulin Pens market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices must be registered with the Health Sciences Authority (HSA), except low-risk Class A devices.[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2] Diabetes (adults): 13.1% of adults in 2022, the latest WHO figure for Singapore.[3]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] CPF Board, MediShield Life. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how smart Insulin Pens products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Singapore.
What doctors and scientists are doing in Smart Insulin Pens right now, from free public sources.
13.1 % of adults
Diabetes (adults), Singapore, 2022 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
From our blog
Singapore
Singapore
Singapore
Singapore
Singapore
Singapore
Digital Health · Singapore
Pharmaceuticals · Singapore
Digital Health · Singapore
Healthcare Services · Singapore
Digital Health · Singapore
Pharmaceuticals · Singapore